Herpes simplex virus type-2 assay specificity and male circumcision to reduce herpes simplex virus type-2 acquisition

AIDS

Volumn 27, Issue 1, 2013, Pages 147-149

  Tobian, Aaron A R ^a,b,c   Kigozi, Godfrey ^c   Wawer, Maria J ^b,c   Serwadda, David ^c,d   Quinn, Thomas C ^a,c,e   Gray, Ronald H ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^d MAKERERE UNIVERSITY   (Uganda)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMCISION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KENYA; LETTER; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; SOUTH AFRICA; UGANDA; VIRUS STRAIN; WART VIRUS;

CIRCUMCISION, MALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; MALE; ULCER;

EID: 84871531348     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835aa181     Document Type: Letter

References (20)

1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-666.
2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656. (Pubitemid 46281312)
3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
4. Tobian AA, Gray RH. The medical benefits of male circumcision. JAMA 2011; 306:1479-1480.
5. Tobian AA, Gray RH, Quinn TC. Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med 2010; 164:78-84.
6. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199:14-19.
7. Smith J, Backes DM, Bailey R, Moses S, Agot K, Maclean IW, et al. The effect of male circumcision on incident and persistent penile HPV infections in men from Kenya. 26th International Papillomavirus Conference 2010.
8. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298-1309.
9. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012; 26:1141-1149.
10. Suntoke TR, Hardick A, Tobian AA, Mposa B, Laeyendecker O, Serwadda D, et al. Evaluation of multiplex real-time PCR for detection of H. ducreyi, T. pallidum, HSV-1, and HSV-2 in the diagnosis of genital ulcer disease in Rakai District, Uganda. Sex Transm Infect 2009; 85:97-101.
11. Brankin AE, Tobian AA, Laeyendecker O, Suntoke TR, Kizza A, Mpoza B, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. Int J STD AIDS 2009; 20:650-651.
12. Tobian AAR, Charvat B, Ssempijja V, Kigozi G, Serwadda D, Makumbi F, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infections among men in Rakai, Uganda. J Infect Dis 2009; 199:945-949.
13. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958-964.
14. Gamiel JL, Tobian AAR, Laeyendecker OB, Reynolds SJ, Morrow RA, Serwadda D, et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 2008; 15:888-890. (Pubitemid 351967018)
15. Hogrefe W, Su X, Song J, Ashley R, Kong L. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, western blotting, and gG2 inhibition. J Clin Microbiol 2002; 40:3635-3640.
16. Laeyendecker O, Henson C, Gray RH, Nguyen RH, Horne BJ, Wawer MJ, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794-1796. (Pubitemid 38500844)
17. van Dyck E, Buve A, Weiss HA, Glynn JR, Brown DW, De Deken B, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004; 42:2961-2965. (Pubitemid 38938043)
18. Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA. Mature glycoprotein G presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different Tanzanian cohorts. Clin Vaccine Immunol 2006; 13:633-639. (Pubitemid 44042850)
19. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530-536. (Pubitemid 38961578)
20. Smith JS, Bailey RC, Westreich DJ, Maclean I, Agot K, Ndinya-Achola JO, et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, western blot and inhibition testing. Sex Transm Infect 2009; 85:92-96.